Efficacy and safety of orally/sublingually, intranasally, and intraperitoneally administered recombinant murine interferon in the treatment of murine encephalomyocarditis virus.

Interferons (IFN) have been shown to be effective in protecting animals against lethal viral infections when administered systemically in relatively high doses. Intraperitoneal (i.p.) injection of mice with encephalomyocarditis virus (EMCV) gives rise to a rapidly progressive fatal disease characterized by central nervous system involvement and encephalitis. IFN-alpha has been shown to be effective in protecting mice against lethal EMCV infection when given via parenteral and oral/sublingual routes. The current study was designed to explore the ability of orally/sublingually and intranasally (i.n.) administered IFN-alpha to treat mice infected with EMCV in support of a planned clinical trial to evaluate efficacy of oral IFN-alpha in human viral infections. The primary objective of the study was to determine the efficacy of recombinant murine IFN-alpha (rMuIFN-alpha) in the treatment of mice infected with 100 LD(50) EMCV following oral, i.n., and i.p. administration at doses of 20,000 and 100,000 IU. The results of the current experiment did not indicate protection from infection with EMCV in mice that received IFN by the i.n. or oral/sublingual routes. The negative controls, infection of mice with 100 LD(50) of EMCV followed by treatment with excipient via all three routes, resulted in death of nearly all mice, as expected. The positive control, treatment of EMCV-infected (100 LD(50)) mice with rMuIFN-alpha via the i.p. route, was successful in protecting a significant number of mice from death compared with matched controls. This study points out the need to determine the optimum conditions for administration of oral/sublingual or i.n. IFN to insure maximum efficacy against viral infections.

SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.

Vascular endothelial growth factor, fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF) and their cognate receptor tyrosine kinases are strongly implicated in angiogenesis associated with solid tumors. Using rational drug design coupled with traditional screening technologies, we have discovered SU6668, a novel inhibitor of these receptors. Biochemical kinetic studies using isolated Flk-1, FGF receptor 1, and PDGF receptor beta kinases revealed that SU6668 has competitive inhibitory properties with respect to ATP. Cocrystallographic studies of SU6668 in the catalytic domain of FGF receptor 1 substantiated the adenine mimetic properties of its oxindole core. Molecular modeling of SU6668 in the ATP binding pockets of the FIk-1/KDR and PDGF receptor kinases provided insight to explain the relative potency and selectivity of SU6668 for these receptors. In cellular systems, SU6668 inhibited receptor tyrosine phosphorylation and mitogenesis after stimulation of cells by appropriate ligands. Oral or i.p. administration of SU6668 in athymic mice resulted in significant growth inhibition of a diverse panel of human tumor xenografts of glioma, melanoma, lung, colon, ovarian, and epidermoid origin. Furthermore, intravital multifluorescence videomicroscopy of C6 glioma xenografts in the dorsal skinfold chamber model revealed that SU6668 treatment suppressed tumor angiogenesis. Finally, SU6668 treatment induced striking regression of large established human tumor xenografts. Investigations of SU6668 activity in cancer patients are ongoing in Phase I clinical trials.

Targeting angiogenesis inhibits tumor infiltration and expression of the pro-invasive protein SPARC.

The solid growth of high-grade glioma appears to be critically dependent on tumor angiogenesis. It remains unknown, however, whether the diffuse infiltration of glioma cells into healthy adjacent tissue is also dependent on the formation of new tumor vessels. Here, we analyze the relationship between tumor angiogenesis and tumor cell infiltration in an experimental glioma model. C6 cells were implanted into the dorsal skinfold chamber of nude mice, and tumor angiogenesis was monitored by intravital fluorescence videomicroscopy. Glioma infiltration was assessed by the extent of tumor cell invasion into the adjacent chamber tissue and by expression of SPARC, a cellular marker of glioma invasiveness. To test the hypothesis that glioma angiogenesis and glioma infiltration are codependent, we assessed tumor infiltration in both the presence and the absence of the angiogenesis inhibitor SU5416. SU5416 is a selective inhibitor of the VEGF/Flk-1 signal-transduction pathway, a critical pathway implicated in angiogenesis. Control tumors demonstrated both high angiogenic activity and tumor cell invasion accompanied by strong expression of SPARC in invading tumor cells at the tumor-host tissue border. SU5416-treated tumors demonstrated reduced vascular density and vascular surface in the tumor periphery accompanied by marked inhibition of glioma invasion and decreased SPARC expression. A direct effect of SU5416 on glioma cell motility and invasiveness was excluded by in vitro migration and invasion assays. These results suggest a crucial role for glioma-induced angiogenesis as a prerequisite for diffuse tumor invasion and a possible therapeutic role for anti-angiogenic compounds as inhibitors of both solid and diffuse infiltrative tumor growth.

SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.

SU5416, a novel synthetic compound, is a potent and selective inhibitor of the Flk-1/KDR receptor tyrosine kinase that is presently under evaluation in Phase I clinical studies for the treatment of human cancers. SU5416 was shown to inhibit vascular endothelial growth factor-dependent mitogenesis of human endothelial cells without inhibiting the growth of a variety of tumor cells in vitro. In contrast, systemic administration of SU5416 at nontoxic doses in mice resulted in inhibition of subcutaneous tumor growth of cells derived from various tissue origins. The antitumor effect of SU5416 was accompanied by the appearance of pale white tumors that were resected from drug-treated animals, supporting the antiangiogenic property of this agent. These findings support that pharmacological inhibition of the enzymatic activity of the vascular endothelial growth factor receptor represents a novel strategy for limiting the growth of a wide variety of tumor types.

Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy.

Vascular endothelial growth factor (VEGF) plays a fundamental role in mediating tumor angiogenesis and tumor growth. Here we investigate the direct effect of a novel small molecule inhibitor of the Flk-1-mediated signal transduction pathway of VEGF, SU5416, on tumor angiogenesis and microhemodynamics of an experimental glioblastoma by using intravital multifluorescence videomicroscopy. SU5416 treatment significantly suppressed tumor growth. In parallel, SU5416 demonstrated a potent antiangiogenic activity, resulting in a significant reduction of both the total and functional vascular density of the tumor microvasculature, which indicates an impaired vascularization as well as significant perfusion failure in treated tumors. This malperfusion was not compensated for by changes in vessel diameter or recruitment of nonperfused vessels. Analyses of the tumor microcirculation revealed significant microhemodynamic changes after angiogenesis blockage such as a higher red blood cell velocity and blood flow in remnant tumor vessels when compared with controls. Our results demonstrate that the novel antiangiogenic concept of targeting the tyrosine kinase of Flk-1/KDR by means of a small molecule inhibitor represents an efficient strategy to control growth and progression of angiogenesis-dependent tumors. This study provides insight into microvascular consequences of Flk-1/KDR targeting in vivo and may have important implications for the future treatment of angiogenesis-dependent neoplasms.

Inhibition of lipopolysaccharide-induced interleukin-1 beta mRNA expression in mouse macrophages by oxidized low density lipoprotein.

Recent studies have demonstrated the expression of messenger RNA (mRNA) for several cytokines within atherosclerotic arteries. Since cytokines have been shown to modulate functions of cultured arterial wall cells in a manner that could influence atherogenesis, this suggests that factors that modulate cytokine production would influence the atherosclerotic process. To examine whether lipoproteins can modulate cytokine production, the effect of lipoproteins on mouse macrophage interleukin-1 beta (IL-1 beta) mRNA expression was examined by dot blot and Northern blot analyses. Low density lipoprotein (LDL), acetylated-LDL, or malondialdehyde-LDL did not induce IL-1 beta mRNA expression or affect the expression in response to lipopolysaccharide (LPS). Similarly, copper ion-oxidized LDL did not stimulate the production of IL-1 beta mRNA. However, oxidized LDL inhibited the LPS-induced expression in a concentration- and time-dependent manner with a maximum inhibition (greater than 90%) observed after a 2.5 h preincubation with 25 micrograms protein/ml. These conditions did not affect protein synthesis or phagocytosis and the inhibition was partially reversible after 24 h, which together suggest that the inhibition was not due to cell death. An inhibition of IL-1 alpha and IL-6 mRNA expression was also observed while there was no change in gamma-actin mRNA levels. The level of inhibition of IL-1 beta mRNA was dependent upon the extent of LDL oxidation, but did not correlate with recognition by the scavenger receptor. A non-receptor pathway was supported by two lines of evidence: 1) the inhibition could be reproduced with a lipid extract, and 2) oxidized LDL also inhibited scavenger receptor negative THP-1 cell IL-1 beta mRNA expression. Finally, oxidized LDL had no effect on the turnover of IL-1 beta mRNA, suggesting that the decreased accumulation of IL-1 beta mRNA is due to a decrease in gene transcription. Together these studies suggest that as macrophages become foam cells their immune responsiveness is attenuated.

Inhibition of mouse macrophage degradation of acetyl-low density lipoprotein by interferon-gamma.

In vitro, metabolism of modified forms of low density lipoprotein (LDL) by macrophages via the acetyl-LDL receptor pathway promotes the massive cellular accumulation of lipid. It has been postulated that in vivo this contributes to foam cell formation in the atherosclerotic lesion. Recent studies have shown that arterial wall cells in vitro can secrete a number of cytokines, several of which have been reported to modulate macrophage cell function. Thus, cytokines have the potential to modulate the acetyl-LDL receptor pathway and to influence the rate of foam cell generation. To study the regulation of this pathway by cytokines, the effect of cytokines on the degradation of acetyl-LDL protein by mouse peritoneal macrophages was examined. Initially, supernatant from stimulated lymphocytes was used as a source of cytokines. Macrophages preincubated with supernatants obtained after the stimulation of T-cell helper type 1 (Th1) clone HDK-1 or BALB/c spleen cells degraded acetyl-LDL at a slower rate, whereas supernatant from stimulated T-cell helper type 2 (Th2) clone D-10 had no effect. Comparison of the lymphokine profiles showed that spleen and HDK-1 cells secreted several lymphokines in common including significant levels of interferon-gamma. Interferon-gamma was then directly shown to be inhibitory; an anti-interferon-gamma monoclonal antibody blocked the HDK-1-mediated inhibition by 70% and the addition of recombinant interferon-gamma (IFN-gamma) to macrophages inhibited the specific degradation of acetyl-LDL in a dose- and time-dependent manner with a maximum suppression to approximately 40% of control. The inhibition was not accompanied by an increase in the amount of cell-associated acetyl-LDL and was not due to cell death nor could it be accounted for by the presence of endotoxin. To study the mechanism of the inhibition, the effects of IFN-gamma on the itinerary of acetyl-LDL and its receptor were examined. IFN-gamma decreased specific acetyl-LDL binding only to a small degree, and the rate of lysosome-mediated degradation was not affected. The principal alteration was in the rate of transport to the lysosome which was markedly slowed. Since the receptors eventually returned to the surface to maintain a steady state, and there was not an increase in cell-associated lipoprotein, there must be other changes in the itinerary that were not identified with the techniques used. Thus, the receptor cycle is being regulated at a discrete point. IFN-gamma also suppressed the LDL receptor pathway in macrophages, but this pathway was not affected by IFN-gamma in mouse fibroblasts.(ABSTRACT TRUNCATED AT 400 WORDS)

Alloreactive murine CD8+ T cell clones secrete the Th1 pattern of cytokines.

A large panel of CD8+ mouse T cell clones expressed the cytokine synthesis pattern characteristic of Th1 clones. CD8+ clones synthesized IFN-gamma and lymphotoxin at levels similar to Th1 clones, whereas IL-2 was synthesized by only 50% of the clones and at significantly lower levels compared to Th1 clones. CD8+ clones also produced substantial amounts of granulocyte/macrophage-CSF, TY5, P500, and TNF-alpha which are expressed preferentially by Th1 clones and at lower levels by Th2 clones. The level of IL-3 produced by CD8+ clones was approximately 10% of that produced by Th1 and Th2 clones. Some CD8+ clones expressed low levels of the Th2-preferential product preproenkelphalin. None of the CD8+ clones expressed detectable levels of the Th2-specific products IL-4, IL-5, and P600, and the great majority did not express IL-6. The cytokine profile of CD8+ clones is representative of that secreted by activated normal CD8+ splenocytes, which includes IFN-gamma, low levels of IL-2 and IL-3 but no IL-4 or IL-5. Inasmuch as many Th1/Th2 functions are cytokine mediated, the striking similarity of the Th1 and CD8+ cytokine secretion patterns helps to explain why these two cell types share certain functions such as DTH, and also suggests that further common functions may be discovered in the future.

Heterogeneity of mouse helper T cells. Evidence from bulk cultures and limiting dilution cloning for precursors of Th1 and Th2 cells.

Many long term mouse Th clones express either the type 1 or type 2 Th cell (Th1 or Th2) cytokine secretion phenotype. In this report we present two lines of evidence for the existence of additional Th differentiation states. Lectin-stimulated spleen cells secreted moderate levels of IL-2 compared with long term Th1 clones, whereas the levels of other cytokines were more than 100-fold lower than those produced by either Th1 or Th2 clones. This suggests that many spleen cells produce substantial amounts of IL-2 but little or no IL-4, IL-5, IFN-gamma, IL-3, and granulocyte/macrophage-CSF. In contrast to long term Th clones, many short term alloreactive clones displayed cytokine secretion phenotypes intermediate between the Th1 and Th2 patterns. The proportion of recognizable Th1 and Th2 clones at early times in culture was greatly increased by immunization of the mice from which the responder and stimulator cells were derived; Brucella abortus immunization resulted in the isolation of exclusively Th1 clones, whereas infection with Nippostrongylus brasiliensis resulted in a strong trend toward the isolation of Th2 clones. The immunization of mice from which responder cells were derived strongly affected the type of Th clone obtained, whereas the source of stimulator cells had much less effect, suggesting that the commitment of Th cells to the Th1 or Th2 phenotypes occurred mainly in vivo. A model for the possible relationships of the various Th cells is presented.

The role of IFN-gamma in delayed-type hypersensitivity mediated by Th1 clones.

One type of Th cell clone, Th1, causes delayed-type hypersensitivity (DTH) when injected with the appropriate Ag into the footpads of naive mice. Because IFN-gamma, one of the Th1-specific cytokines, has been reported to produce some of the manifestations of DTH, we have investigated the role of IFN-gamma in the DTH reaction induced by Th1 cells by using a mAb which neutralizes the biologic activity of IFN-gamma. Anti IFN-gamma inhibited up to 55% of the swelling response induced by seven Th1 clones in BALB/c and CBA/J mice suggesting that IFN-gamma is an important mediator of Th1-induced DTH. This inhibition was consistently observed during the peak phase of the DTH response and could be partly but not entirely explained by decreases in vascular leakage. The DTH responses induced by two Th1 clones in C57BL/6 mice were not inhibited by anti IFN-gamma. Taken together, these data suggest that other inflammatory mediators also play a role in Th1-induced DTH responses. Based on the gross description and kinetics of the response and the numbers of polymorphonuclear neutrophilic granulocytes in the cellular infiltrate, Th1-induced DTH appears to be similar to the Jones-Mote type of hypersensitivity.

Specific assays for cytokine production by T cells.

Recent advances in understanding of cytokine function have indicated the need for more stringent cytokine assays, and have at the same time provided the information and tools necessary for establishing monospecific assays for a number of T cell-derived cytokines. Monoclonal antibodies are invaluable for improving the specificity of bioassays, both by removing unwanted activities, and in the most stringent assays, for confirming the identity of the cytokine detected. Several cytokines can also be directly measured by ELISA techniques using monoclonal antibodies.